Product image of Lenalidomide supplied by GNH India

Lenalidomide

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide

Lenalidomide, the active ingredient in Lenalidomide, is an immunomodulatory drug presented as an oral tablet for systemic use. It is indicated for the treatment of adult patients with multiple myeloma and for myelodysplastic syndromes that carry the del(5q) chromosomal abnormality, where it helps control disease progression.

GNH India supplies Lenalidomide as a licensed, Good Distribution Practice‑compliant product, providing reliable international sourcing for hospitals, oncology centres, pharmacies and clinics worldwide. The product conforms to EU pharmacopeial standards and undergoes rigorous quality testing before release.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies that involve abnormal plasma‑cell or myeloid proliferation.

  • Multiple myeloma: improves progression‑free survival in adult patients.
  • Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias.
  • Relapsed or refractory disease: provides a therapeutic option after prior therapies.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in anti‑proliferative, immunomodulatory, and anti‑angiogenic effects that suppress malignant cell growth.

Side Effects

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: low platelet count leading to bleeding tendencies.
  • Fatigue: persistent tiredness affecting daily activities.
  • Nausea: upset stomach often occurring after dosing.
  • Diarrhea: loose stools that may require hydration.
  • Constipation: difficulty passing stools.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: profound immune suppression requiring medical intervention.
  • Serious infections: opportunistic or bacterial infections.
  • Second primary malignancies: emergence of new cancers.
  • Hypersensitivity reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known toxicities.

  • Monitor blood counts: perform regular CBC to detect cytopenias.
  • Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients.
  • Avoid use in pregnancy: drug is teratogenic; ensure effective contraception.
  • Renal impairment: adjust dose or monitor renal function closely.
  • Review concomitant medications: check for interactions that may alter efficacy or safety.
  • Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Lenalidomide can interact with several agents, requiring careful management.

Major Interactions (Avoid)

  • Thalidomide: combined use markedly increases thrombosis risk.
  • Anticoagulants: may enhance anticoagulant effect and bleeding.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lenalidomide exposure.
  • Live vaccines: contraindicated due to immunosuppressive potential.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may reduce drug exposure.
  • NSAIDs: can increase risk of renal toxicity.
  • Antihypertensives: monitor blood pressure as lenalidomide may affect vascular tone.

Frequently Asked Questions

Lenalidomide is approved for adult patients with multiple myeloma and for myelodysplastic syndromes that have the del(5q) chromosomal abnormality. In both settings it helps control disease progression and can reduce the need for blood transfusions.

The drug binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, changing its activity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to anti‑proliferative, immunomodulatory, and anti‑angiogenic effects that suppress malignant cell growth.

The prescribed dose of Lenalidomide is individualized by the treating physician based on the specific indication, disease status, renal function, and other patient factors. Patients should follow the dosing instructions provided by their healthcare professional.

Lenalidomide is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, so nursing is generally discouraged.

To request Lenalidomide, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class is thalidomide, another immunomodulatory drug. Lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, and has distinct efficacy in del(5q) myelodysplastic syndromes, whereas thalidomide is often used for multiple myeloma but carries higher neuropathy risk.

Lenalidomide tablets should be stored at ambient temperature below 25 °C, in the original packaging, protected from moisture and light. Do not store in bathrooms or near heat sources to maintain product stability.

Lenalidomide is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The exact schedule (continuous or cyclical) depends on the treatment protocol and patient tolerance.

The most serious risks include severe neutropenia, thrombocytopenia, venous thromboembolism, serious infections, and the potential for second primary malignancies. Patients should be monitored regularly for blood count changes and signs of clotting or infection.

Lenalidomide should not be used by individuals who are pregnant, have uncontrolled infections, have a known hypersensitivity to the drug, or lack appropriate contraception when of child‑bearing potential. Clinicians must also assess renal function before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT